Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma Angiochem, a clinical stage biotechnology firm developing drugs that are uniquely capable of crossing the blood-brain barrier , today announced the initiation of a Stage 2 clinical study with ANG1005, a novel paclitaxel-peptide medication conjugate, in sufferers with recurrent high-grade glioma. This study is designed to measure the anti-tumor activity of ANG1005 as a fresh method of treating primary human brain cancers including recurrent glioblastoma multiforme and anaplastic glioma female sildenafil 100mg . This Phase 2 clinical research follows a previously completed Phase 1 study of ANG1005 in individuals with recurrent glioma in which promising symptoms of anti-tumor activity were noticed.

Related StoriesMeat-rich diet plan may increase kidney cancer riskSausages With Antioxidants From Berries To Prevent CancerMD Anderson study reveals why chemotherapy drugs not effective for most pancreatic cancer patientsThe researchers found that usage of PADT for localized prostate cancer tumor was associated with lower 10-season prostate cancer-specific survival no increase in 10-year overall survival weighed against conservative management. Nevertheless, in a prespecified subset evaluation, PADT use in males with poorly differentiated cancers was associated with improved 10-season prostate cancer-specific survival however, not overall survival . ‘The significant undesireable effects and costs connected with PADT, along with this finding of too little overall survival benefit, claim that clinicians should thoroughly consider the explanation for initiating PADT in elderly individuals with T1-T2 prostate cancer,’ the authors conclude..